The following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the Company’s reportable segment for the three months ended March 31, 2026 and March 31, 2025 (in thousands):


	Three Months Ended March 31, 2026		Three Months Ended March 31, 2025
License and other revenue	$	—	$	15,000
Less:
Cleminorexton¹	(20,503)		(13,666)
Other Orexin program expenses1	(23,758)		(6,427)
LockBody technology program expenses	(1,530)		(3,418)
Discontinued R&D program expenses	52		(2,917)
Other R&D expenses:
Personnel expenses2	(11,714)		(6,302)
Research tax incentives	3,630		4,259
Other internal R&D expenses	(1,983)		(815)
General and administrative expenses¹	(13,402)		(8,608)
Share-based compensation	(10,565)		(7,883)
Interest income	5,138		7,890
Interest expense	(2,731)		(2,877)
Other segment items3	(1,025)		1,026
Income tax expense	(850)		(1,397)
Consolidated net loss	$	(79,241)	$	(26,135)

¹ Beginning December 31, 2025, expenses related to the cleminorexton trial have been identified as significant segment expenses. The expenses for this trial have been recast for periods prior to December 31, 2025. These amounts were previously combined and disclosed under “OX2R program expenses” for the quarter ended March 31, 2025.
² Excludes share-based compensation which is presented separately below
3 Other segment items includes Other non-operating income (expense), net